Nektar Therapeutics CEO Howard Robin's 2021 pay slips 1% to $11M
Nektar Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
Nektar Therapeutics reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, five executives at Nektar Therapeutics received on average a compensation package of $5.7M, which is about the same as previous year.
Average pay of disclosed executives at Nektar Therapeutics
Howard W. Robin, Chief Executive Officer, received $11M in total, which decreased by 1% compared to 2020. 51% of Robin's compensation, or $5.7M, was in stock awards. Robin also received $1M in non-equity incentive plan, $3.3M in option awards, $1.1M in salary, as well as $82K in other compensation.
Gil M. Labrucherie, Chief Financial Officer, received a compensation package of $5.3M, which is about the same as previous year. 45% of the compensation package, or $2.4M, was in stock awards.
Jonathan Zalevsky, Senior Vice President and Chief Research and Development Officer, earned $5M in 2021, which is about the same as previous year.
John Northcott, Senior Vice President and Chief Commercial Officer, received $3.8M in 2021, which decreases by 1% compared to 2020.
Mark A. Wilson, General Counsel, earned $3.5M in 2021, a 1% increase compared to previous year.
Related executives
Howard Robin
Nektar Therapeutics
Chief Executive Officer
Gil Labrucherie
Nektar Therapeutics
Chief Financial Officer
John Northcott
Nektar Therapeutics
Senior Vice President and Chief Commercial Officer
Mark Wilson
Nektar Therapeutics
General Counsel
Jonathan Zalevsky
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
You may also like
Source: SEC filing on April 29, 2022.